Shopping Cart

0 items
  1. ProMedications News
  2. We offer a wide range of anabolic steroids, which have a different direction. Here you can buy anabolic steroids for muscle mass gain, as well as steroids for cutting cycles. There are also drugs available that help to lose weight, to cut and preserve the results that you have gained by using steroids. To buy anabolic steroids - its not complicated because the Internet today offers many possibilities to buy anabolic steroids online. At http://www.promedications.com you can buy steroids with 100% guarantee of delivery. Do not hesitate, order. Hundreds of people have been working with us, and the number of our clients is constantly growing. To buy anabolic steroids look for trusted people and do not entertain any illusions.

    Our catalog includes the most popular steroids collected from around the world. We do not sell substandard drugs, or "dummy" steroids. Our suppliers regularly provide us with products from Spain, Greece, Pakistan, India, Turkey and other countries.

    After reviewing the menu of our online store, you can find answers to your questions: guarantees, payment terms, delivery, how to buy anabolic steroids, etc. If you still have any questions, or maybe you are a beginner and need to consult with a qualified specialists for the compilation of the correct course of treatment with steroids and high-quality selection of products, then please contact us by e-mail. We must and will supply the answers to any of your questions regarding how to buy steroids online.
    More news...

Azulfidine

Azulfidine
Click to enlarge

Reviews
$0.18
Manufacturer: Generic, India
Pharmaceutical name:
Pack: 1 tab (500 mg)


Azulfidine is a drug that is used primarily for treating ulcerative colitis. Azulfidine affects a substance in the body that causes inflammation, tissue damage, and diarrhea. Azulfidine is used to treat moderate to severe ulcerative colitis. It is also used to treat rheumatoid arthritis in children and adults who have received other arthritis medications without successful treatment of symptoms.

Azulfidine is used for the treatment of mild to severe ulcerative colitis, and treatment of rheumatoid arthritis. It has also been used "off label" (unapproved by the FDA) for Crohn's disease and ankylosing spondylitis.

Dosing:
Adult doses range from 1000 mg to 4000 mg daily. Azulfidine is administered 2 to 4 times daily depending on the disease for which it is used. Azulfidine should be taken with a full glass of water after meals or with food to minimize upset stomach. Patients with kidney diseases may need to use lower doses of sulfasalazine.

Pregnancy:
In hundreds of pregnant women with ulcerative colitis or Crohn's disease treated with sulfasalazine, there has been no increase in the risk of fetal malformations relative to other women with these illnesses who have not been treated with sulfasalazine. Additionally, there have not been ill effects on pregnant animals given high doses of sulfasalazine. Thus, sulfasalazine may be used during pregnancy if the physician feels the benefit outweighs the possible risk. It should also be noted, however, that sulfasalazine may reduce sperm count and sperm function in men. These effects are reversible upon stopping the drug.

Side Effects:
Gastrointestinal disturbances frequently occur in patients taking sulfasalazine. Nausea, vomiting, gastric distress, and anorexia (loss of appetite) commonly occur. Sulfasalazine may cause the skin or the urine to change color. Development of an orange-yellow discoloration is no cause for concern. Headache, allergic reactions, and photosensitivity (development of a rash when exposed to sunlight) may develop during sulfasalazine therapy and require medical attention. Some of the allergic reactions may progress from a rash to difficulty in swallowing, blistering, peeling, or loosening of the skin, aching joints and muscles, and unusual tiredness or weakness. It may be accompanied by fever. The more severe allergic reactions are rare.

This product was added to our catalog
on Friday 22 April, 2011.



Currently viewing: